Tirzepatide
Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist with the strongest clinical weight loss data of any approved agent to date.
Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). This page discusses the compound in a research context. The approved forms are prescription-only and should be used under physician supervision. Research-grade tirzepatide sold by compound vendors is not the same as the FDA-approved product and is not approved for human use in that form.
What it is
Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Developed by Eli Lilly, it received FDA approval as Mounjaro for type 2 diabetes and Zepbound for weight management.
The dual action on both GIP and GLP-1 receptors appears to produce additive metabolic benefits beyond either mechanism alone.
What research shows
- 20.9% average body weight reduction at 72 weeks in SURMOUNT-1 (10mg and 15mg doses)
- Superior weight loss versus semaglutide 1mg in head-to-head SURPASS-2 trial
- Significant HbA1c reduction in type 2 diabetes
- Favorable cardiovascular and metabolic biomarker profile
- Potential lean mass preservation compared to older weight loss approaches
What remains unknown
- Long-term effects beyond current trial windows
- Weight regain trajectory after discontinuation
- Optimal maintenance dosing strategies
- Full cardiovascular outcome trial results (ongoing)
Administration basics
Common use cases
Weight management, type 2 diabetes, metabolic health optimization.
Half-life
~5 days (weekly dosing).
Administration
Subcutaneous injection once weekly.
Research Protocols & Common Usage
Doses used in research
- SURMOUNT trials started at 2.5mg/week subcutaneously for 4 weeks
- Titrated to target doses of 5mg, 10mg, or 15mg/week
Administration routes studied
Typical protocol duration
SURMOUNT-1 ran 72 weeks. Clinical use is long-term with ongoing monitoring.
Common stacking protocols
- Tirzepatide is used as a standalone medication; combination with other incretin therapies is not studied and not recommended
Contraindications & combinations to avoid
- Personal or family history of medullary thyroid carcinoma — same black box warning as semaglutide
- MEN2 — contraindicated
- History of pancreatitis
- Should never be combined with semaglutide, liraglutide, or any other GLP-1 or GIP agonist
Dosing information reflects doses used in published research and commonly reported community protocols only. This is not a personal recommendation. These compounds are not FDA-approved for human use in the contexts described. Consult a qualified healthcare provider before starting any protocol.
Considering stacking?
See the stacking guide for common combinations with Tirzepatide and what to avoid.
Track your Tirzepatide protocol
Log your experience, track outcomes over time, and get AI-powered interpretation of your results after 14 days of data. Private, $14.99/month.
Start trackingGet research updates
We'll notify you when we update the Tirzepatide page or publish related research.
More in the library
Community Reviews
Reviews reflect individual user experiences with research compounds and are not medical advice. Results vary. These compounds are not FDA approved for human use. Peptelligent does not verify reported experiences.
Write a Review
No reviews yet. Be the first to share your experience.